Literature DB >> 19996282

Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3.

Zhuohan Zhang1, Qiaofei Liu, Yongzhe Che, Xin Yuan, Lingyun Dai, Bin Zeng, Guohui Jiao, Yin Zhang, Xue Wu, Yinyan Yu, Yuan Zhang, Rongcun Yang.   

Abstract

Dendritic cell (DC) function is negatively affected by tumors and tumor-derived factors, but little is known about the underlying mechanisms. Here, we show that intracellular SOCS3 in DCs binds to pyruvate kinase type M2 (M2-PK), which plays a critical role in ATP production through glycolysis. The interaction of SOCS3 with M2-PK reduced ATP production and impaired DC-based immunotherapy against tumors. Thus, SOCS3, which has been shown to be upregulated by tumor-derived factors, interacts with M2-PK to decrease ATP production, causing DC dysfunction. These dysfunctional DCs have a reduced ability to present antigens. Alteration of DC metabolism mediated by SOCS3 represents a novel mechanism for DC dysfunction in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19996282     DOI: 10.1158/0008-5472.CAN-09-2970

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Human pyruvate kinase M2: a multifunctional protein.

Authors:  Vibhor Gupta; Rameshwar N K Bamezai
Journal:  Protein Sci       Date:  2010-11       Impact factor: 6.725

2.  Lentivirally engineered dendritic cells activate AFP-specific T cells which inhibit hepatocellular carcinoma growth in vitro and in vivo.

Authors:  Yang Liu; Lisa H Butterfield; Xiaohui Fu; Zhenshun Song; Xiaoping Zhang; Chongde Lu; Guanghui Ding; Mengchao Wu
Journal:  Int J Oncol       Date:  2011-04-13       Impact factor: 5.650

Review 3.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

4.  Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.

Authors:  Bernice Y Yan; Sandra Garcet; Nicholas Gulati; Felix Kiecker; Judilyn Fuentes-Duculan; Patricia Gilleaudeau; Mary Sullivan-Whalen; Avner Shemer; Hiroshi Mitsui; James G Krueger
Journal:  Exp Dermatol       Date:  2018-12-21       Impact factor: 3.960

Review 5.  A critical review of the role of M2PYK in the Warburg effect.

Authors:  Robert A Harris; Aron W Fenton
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2019-01-29       Impact factor: 10.680

Review 6.  Anti-tumor immunity: myeloid leukocytes control the immune landscape.

Authors:  Melanie R Rutkowski; Tom L Stephen; Jose R Conejo-Garcia
Journal:  Cell Immunol       Date:  2012-07-14       Impact factor: 4.868

7.  Pyruvate kinase M2 is a novel diagnostic marker and predicts tumor progression in human biliary tract cancer.

Authors:  Dipok Kumar Dhar; Steven W M Olde Damink; James Hal Brindley; Andrew Godfrey; Michael H Chapman; Neomal S Sandanayake; Fausto Andreola; Sybille Mazurek; Tayyaba Hasan; Massimo Malago; Stephen P Pereira
Journal:  Cancer       Date:  2012-08-01       Impact factor: 6.860

Review 8.  SOCS3, a Major Regulator of Infection and Inflammation.

Authors:  Berit Carow; Martin E Rottenberg
Journal:  Front Immunol       Date:  2014-02-19       Impact factor: 7.561

Review 9.  Metabolic control of dendritic cell activation and function: recent advances and clinical implications.

Authors:  Bart Everts; Edward J Pearce
Journal:  Front Immunol       Date:  2014-05-08       Impact factor: 7.561

10.  Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.

Authors:  Jared S Klarquist; Edith M Janssen
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.